James Liao to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications James Liao has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
11.132
-
Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023 06; 97(6):1529-1545.
Score: 0.710
-
Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res. 2022 01 29; 118(2):413-423.
Score: 0.652
-
The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Curr Vasc Pharmacol. 2019; 17(3):222-232.
Score: 0.527
-
Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017 Jan 06; 120(1):229-243.
Score: 0.459
-
Evidence of pleiotropy by statins: leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. Int J Cardiol. 2014 Sep; 176(1):250-3.
Score: 0.386
-
Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal. 2014 Mar 10; 20(8):1251-67.
Score: 0.366
-
Mitohormesis: another pleiotropic effect of statins? Eur Heart J. 2012 Jun; 33(11):1299-301.
Score: 0.319
-
Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation. 2011 May 10; 123(18):1925-8.
Score: 0.309
-
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J. 2010 May; 74(5):818-26.
Score: 0.288
-
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009; 15(5):467-78.
Score: 0.264
-
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol. 2009 Feb 15; 103(4):437-41.
Score: 0.263
-
Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab. 2008 Jul; 28(7):1285-93.
Score: 0.250
-
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008 Jan; 14(1):37-44.
Score: 0.246
-
Does it matter whether or not a lipid-lowering agent inhibits Rho kinase? Curr Atheroscler Rep. 2007 Nov; 9(5):384-8.
Score: 0.243
-
Safety and efficacy of statins in Asians. Am J Cardiol. 2007 Feb 01; 99(3):410-4.
Score: 0.229
-
Rho GTPases, statins, and nitric oxide. Circ Res. 2005 Dec 09; 97(12):1232-5.
Score: 0.213
-
Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005 Dec; 16(6):624-9.
Score: 0.213
-
Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med. 2005 Nov; 2(11):576-84.
Score: 0.212
-
Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005 Sep 05; 96(5A):24F-33F.
Score: 0.209
-
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118.
Score: 0.200
-
Statins: potent vascular anti-inflammatory agents. Int J Clin Pract Suppl. 2004 Oct; (143):41-8.
Score: 0.196
-
Statins and myocardial hypertrophy. Coron Artery Dis. 2004 Aug; 15(5):247-50.
Score: 0.194
-
Statin therapy: having the good without the bad. Hypertension. 2004 Jun; 43(6):1171-2.
Score: 0.192
-
Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 2004 May; 52(4):248-53.
Score: 0.191
-
Lipid management with statins. The lower the better? Z Kardiol. 2004 Jan; 93(1):4-9.
Score: 0.186
-
Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003 Sep; 5(5):372-8.
Score: 0.182
-
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003 Aug 19; 108(7):839-43.
Score: 0.181
-
Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003 May 01; 23(5):729-36.
Score: 0.176
-
Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol. 2003 Feb 01; 23(2):156-7.
Score: 0.175
-
A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003; 35(6):398-403.
Score: 0.174
-
Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002 Nov; 86(1):5-18.
Score: 0.172
-
Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002 Aug; 110(3):285-8.
Score: 0.169
-
Statins and ischemic stroke. Atheroscler Suppl. 2002 May; 3(1):21-5.
Score: 0.166
-
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 Nov; 21(11):1712-9.
Score: 0.160
-
Challenging Statin Pleiotropy: Preeclampsia. Circulation. 2021 08 31; 144(9):680-683.
Score: 0.158
-
Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000 May; 10(4):143-8.
Score: 0.145
-
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999 Jul 30; 274(31):21926-31.
Score: 0.137
-
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998 Jul 21; 95(15):8880-5.
Score: 0.128
-
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 Mar 31; 97(12):1129-35.
Score: 0.125
-
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997 Dec 12; 272(50):31725-9.
Score: 0.123
-
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol. 2013 Jul; 33(7):1591-600.
Score: 0.089
-
Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF. Lab Invest. 2011 May; 91(5):691-703.
Score: 0.076
-
Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011 Mar; 32(3):167-73.
Score: 0.076
-
Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev Neurother. 2009 Aug; 9(8):1171-86.
Score: 0.069
-
Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des. 2009; 15(27):3108-15.
Score: 0.066
-
Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009 Aug; 205(2):517-21.
Score: 0.066
-
Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. Can J Physiol Pharmacol. 2008 Sep; 86(9):633-42.
Score: 0.064
-
Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol. 2007 Apr; 292(4):H1937-42.
Score: 0.057
-
Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 2006 Jun; 85(6):520-3.
Score: 0.055
-
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005 Jun; 25(6):722-9.
Score: 0.051
-
Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res. 2004 Jul 23; 95(2):217-23.
Score: 0.048
-
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004 Jun; 39(6):1178-85.
Score: 0.048
-
Targeting eNOS for stroke protection. Trends Neurosci. 2004 May; 27(5):283-9.
Score: 0.048
-
Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol. 2004 Mar; 43(3):454-61.
Score: 0.047
-
Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res. 2003 Nov 01; 60(2):250-8.
Score: 0.046
-
Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003 Aug 20; 42(4):690-7.
Score: 0.045
-
Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol. 2003 Mar; 41(3):474-80.
Score: 0.044
-
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001 Apr; 32(4):980-6.
Score: 0.039
-
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000 Dec 19; 102(25):3104-10.
Score: 0.038
-
Targeting Rho in cardiovascular disease. Circ Res. 2000 Sep 29; 87(7):526-8.
Score: 0.037
-
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
Score: 0.033
-
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998 Sep 11; 273(37):24266-71.
Score: 0.032
-
[New findings on the action of HMG-CoA-reductase inhibitors]. Dtsch Med Wochenschr. 1997 Oct 10; 122(41):1255-9.
Score: 0.030
-
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
Score: 0.028
-
Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab. 2000 Apr; 20(4):709-17.
Score: 0.009